Drug Database
PE

pembrolizumab

✓ Approved

Dako · CD274 · 辅助诊断

什么是 pembrolizumab?

pembrolizumab 是一种辅助诊断,由Dako研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

公司Dako
药物类别辅助诊断
分子靶点CD274
给药途径Others
状态Approved

作用机制

分子靶点

pembrolizumab 作用于 1 个分子靶点:

CD274CD274 molecule (B7H1, B7-H)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pembrolizumab 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedIJU case reports2026-11-17

Adrenal Insufficiency After Preoperative Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced Bladder Cancer: A Case Report.

Takahashi Takayuki T, Takamatsu Kimiharu K, Igarashi Daisuke D, Umezawa Yuta Y et al.

Enfortumab vedotin (EV) plus pembrolizumab is gaining widespread use in perioperative urothelial carcinoma management. However, perioperative immune-related adverse events (irAEs) may mimic postoperative complications, leading to diagnostic delays. A 79-year-old man with locally advanced bladder cancer (cT3bN0M0) received four cycles of EV plus pembrolizumab, followed by radical cystectomy with pathological complete response (ypT0N0). On postoperative Day 25, he developed fever, anorexia, and fatigue. Endocrine evaluation showed low adrenocorticotropic hormone and cortisol levels, leading to a diagnosis of adrenal insufficiency. Corticosteroid replacement therapy resulted in rapid clinical improvement. Adrenal insufficiency should be recognized as a potential irAE following immune checkpoint inhibitor (ICI) therapy. In patients with prior ICI exposure, nonspecific postoperative symptoms require a high index of suspicion and early endocrine evaluation.

PMID 43041208
阅读全文 →
PubMedBreast cancer research : BCR2026-11-17

Mid-treatment radiologic response as an early predictor of pathologic response in TNBC in the era of pembrolizumab.

Bae Soong June SJ, Eun Na Lae NL, Kim Jee Hung JH, Kook Yoonwon Y et al.

Breast MRI is used to monitor neoadjuvant chemotherapy (NAC) response in triple-negative breast cancer (TNBC), yet its predictive value for pathologic complete response (pCR) in the era of carboplatin and pembrolizumab remains incompletely defined. We analyzed 517 TNBC patients who underwent serial MRI (baseline, mid-treatment, post-NAC) across three regimens: non-carboplatin (n = 225), carboplatin (n = 148), and pembrolizumab (n = 144). Associations between radiologic complete response (rCR) and pCR were evaluated. Mid-treatment rCR rates were highest with pembrolizumab (24.3%), followed by carboplatin (12.8%) and non-carboplatin (11.6%). Pembrolizumab independently increased mid-treatment rCR (adjusted OR 3.13; 95% CI 1.67-5.91; p < 0.001). Mid-treatment rCR was a strong predictor of pCR across all regimens (adjusted OR 26.36; 95% CI 9.30-74.69; p < 0.001), with a stronger association than post-NAC rCR (adjusted OR 8.92; 95% CI 5.58-14.23; p < 0.001). Within each NAC regimen, mid-treatment rCR was a strong predictor of pCR, and pembrolizumab was associated with a higher likelihood of early radiologic response. Given the retrospective, single-center design spanning an extended period, these findings should be interpreted as hypothesis-generating and provide a rationale for prospective, response-adapted trials evaluating mid-treatment MRI in TNBC.

PMID 43040430
阅读全文 →
PubMedDrugs in context2026-11-17

Rapid symptomatic and radiological response to pembrolizumab-lenvatinib in a 30-year-old man with metastatic sarcomatoid renal cell carcinoma not otherwise specified and extensive osteolytic bone disease.

Novero Giorgia G, Cavaglià Isabella I, Delsedime Luisa L, Depetris Ilaria I et al.

Sarcomatoid dedifferentiation and bone metastases characterize an aggressive subset of metastatic renal cell carcinoma (mRCC) with a poor prognosis. Immune-checkpoint inhibitor combinations are the standard first-line therapy, whilst the role of deferred cytoreductive nephrectomy (dCN) remains debated. We report on the case of a 30-year-old man with International mRCC Database Consortium (IMDC)-classified poor-risk mRCC featuring sarcomatoid dedifferentiation and symptomatic osteolytic bone lesions. First-line pembrolizumab-lenvatinib and bone-targeted agents were initiated. Treatment was well tolerated, achieving rapid symptomatic relief and durable disease control. Following durable disease control, the patient underwent dCN. Histopathological analysis confirmed sarcomatoid RCC, not otherwise specified (ypT1b) with extensive necrosis. Pembrolizumab-lenvatinib was resumed 4 weeks postoperatively. Subsequent restaging demonstrated substantial disease stability. This case highlights the efficacy of pembrolizumab-lenvatinib in achieving rapid clinical benefit in sarcomatoid mRCC with symptomatic bone involvement and the opportunity to perform dCN for carefully selected patients after a case-by-case multidisciplinary discussion.

PMID 43042400
阅读全文 →
PubMedDrugs in context2026-11-17

Pembrolizumab plus lenvatinib in first-line metastatic renal cell carcinoma: a single-institution experience and a case of severe treatment-related toxicity with durable tumour control.

Malgeri Andrea A, Sirgiovanni Grazia G, Cerbone Linda L, Bassanelli Maria M et al.

Pembrolizumab plus lenvatinib is a standard first-line treatment for metastatic renal cell carcinoma (mRCC) based on the phase III CLEAR trial. Real-world data are needed to assess effectiveness and toxicity management in routine practice. We report a retrospective single-institution experience and a case of grade 4 immune-related pancreatitis followed by sustained tumour control after treatment discontinuation. We retrospectively analysed consecutive patients with mRCC treated with first-line pembrolizumab plus lenvatinib at IRCCS Regina Elena from March 2024 through March 2026, with clinical follow-up updated through September 2026. The primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety outcomes, including dose modifications and permanent treatment discontinuations. Survival was estimated by the Kaplan-Meier method. Thirty-eight patients were treated, and all were evaluable for response. ORR was 78.9% (4 complete responses and 26 partial responses). At a median follow-up of 11.7 months (95% CI 10.8-18.7), median PFS was not reached (95% CI 19.0-NR) and median OS was not reached (95% CI NR-NR). The estimated 12-month PFS and OS rates were 75.1% and 91.7%, respectively. Grade ≥3 adverse events occurred in 39.5% of patients. Lenvatinib was temporarily interrupted in 71.1% and dose-reduced in 60.5%. Permanent discontinuation due to toxicity occurred in 5.3% for lenvatinib and 15.8% for pembrolizumab; both agents were permanently discontinued in 2 (5.3%) patients. A representative case involved a 37-year-old woman who achieved an early partial response but developed grade 4 immune-related pancreatitis requiring high-dose corticosteroids (2 mg/kg) and second-line immunosuppression with mycophenolate mofetil and everolimus. Despite permanent discontinuation of both agents, partial response persisted at the August 2026 data cutoff. In this real-world cohort, pembrolizumab plus lenvatinib demonstrated high response rates and manageable toxicity consistent with pivotal trial data. Proactive dose modulation allowed treatment continuation in most patients, underscoring the importance of effective management of severe treatment-related toxicity in combination regimens to ensure optimal clinical outcomes in routine clinical settings.

PMID 43042397
阅读全文 →
PubMedDrugs in context2026-11-17

Complete pathological response of bone metastasis in metastatic renal cell carcinoma treated with pembrolizumab plus lenvatinib after surgical debulking and palliative radiotherapy: a case report.

Izzo Michela M, Pappalardo Annalisa A, D'Arienzo Andrea A, Barraco Chiara C et al.

Metastatic renal cell carcinoma (mRCC) presents with marked biological heterogeneity, and bone involvement is associated with aggressive disease and limited response to systemic therapies. We report the case of a 33-year-old female patient with clear cell mRCC who developed metastatic progression after undergoing curative-intent surgery, presenting with vertebral bone metastasis at C7 and peritoneal carcinomatosis. First-line treatment with pembrolizumab plus lenvatinib was initiated, leading to a deep and durable response. A radiological complete response was achieved at all metastatic sites, and subsequent surgery confirmed histological complete remission in the bone lesion. Pathologically documented complete responses in bone metastases from RCC are remarkably rare. This case highlights the potential of immune-checkpoint inhibitor-tyrosine kinase inhibitor combinations to induce profound responses even in unfavourable metastatic patterns and supports a multidisciplinary treatment strategy.

PMID 43042389
阅读全文 →
PubMedDrugs in context2026-11-17

Pembrolizumab and lenvatinib-associated pemphigoid-like dermatosis in advanced renal cell carcinoma: the hidden cost of synergy successfully managed with dupilumab - a case report.

Doronzo Antonio A, Monterisi Santa S, Ciciriello Federica F, Gadaleta-Caldarola Gennaro G

Immune-checkpoint inhibitors have reshaped the therapeutic armamentarium of advanced renal cell carcinoma while increasing the incidence of immune-related adverse events. Among these, bullous dermatoses are rare but potentially severe and therapeutically challenging. We report a case of pemphigoid-like dermatosis induced by pembrolizumab and lenvatinib in a patient affected by metastatic renal cell carcinoma. Initial management with systemic corticosteroids led to complete clinical remission; however, early relapse with vesiculo-bullous erythema required treatment escalation with the introduction of dupilumab. We discuss the underlying immunopathogenesis, differential diagnosis and multidisciplinary management strategies in accordance with current international guidelines and the literature. We also highlight the feasibility of effectively managing treatment-related cutaneous toxicity with dupilumab, allowing continuation of oncological therapy without compromising disease control. Multidisciplinary, tailored-patient treatment workups remain the gold standard for the management of these toxicities.

PMID 43042219
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多pembrolizumab